Search

Your search keyword '"Zebenholzer, Karin"' showing total 150 results
Start Over Author "Zebenholzer, Karin"
150 results on '"Zebenholzer, Karin"'

2. Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe

Author

Goßrau, Gudrun, Förderreuther, Stefanie, Ruscheweyh, Ruth, Ruschil, Victoria, Sprenger, Till, Lewis, David, Kamm, Katharina, Freilinger, Tobias, Neeb, Lars, Malzacher, Volker, Meier, Uwe, Gehring, Klaus, Kraya, Torsten, Dresler, Thomas, Schankin, Christoph J., Gantenbein, Andreas R., Brössner, Gregor, Zebenholzer, Karin, Diener, Hans-Christoph, Gaul, Charly, and Jürgens, Tim P.

Published
2023
Full Text
View/download PDF

4. Erratum zu: Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe

Author

Goßrau, Gudrun, Förderreuther, Stefanie, Ruscheweyh, Ruth, Ruschil, Victoria, Sprenger, Till, Lewis, David, Kamm, Katharina, Freilinger, Tobias, Neeb, Lars, Malzacher, Volker, Meier, Uwe, Gehring, Klaus, Kraya, Torsten, Dresler, Thomas, Schankin, Christoph J., Gantenbein, Andreas R., Brössner, Gregor, Zebenholzer, Karin, Diener, Hans-Christoph, Gaul, Charly, and Jürgens, Tim P.

Published
2023
Full Text
View/download PDF

5. Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS

Author

Zrzavy, Tobias, primary, Rieder, Kerstin, additional, Wuketich, Viktoria, additional, Thalhammer, Renate, additional, Haslacher, Helmuth, additional, Altmann, Patrick, additional, Kornek, Barbara, additional, Krajnc, Nik, additional, Monschein, Tobias, additional, Schmied, Christiane, additional, Zebenholzer, Karin, additional, Zulehner, Gudrun, additional, Berger, Thomas, additional, Rommer, Paulus, additional, Leutmezer, Fritz, additional, and Bsteh, Gabriel, additional

Published
2024
Full Text
View/download PDF

6. Retinal Layer Thinning for Monitoring Disease-modifying Treatment in Relapsing Multiple Sclerosis—Evidence for Applying a Rebaselining Concept (P6-6.005)

Author

Bsteh, Gabriel, primary, Hegen, Harald, additional, Krajnc, Nik, additional, Altmann, Patrick, additional, Auer, Michael, additional, Berek, Klaus, additional, Kornek, Barbara, additional, Leutmezer, Fritz, additional, Macher, Stefan, additional, Monschein, Tobias, additional, Ponleitner, Markus, additional, Rommer, Paulus, additional, Schmied, Christiane, additional, Zebenholzer, Karin, additional, Zulehner, Gudrun, additional, Zrzavy, Tobias, additional, Deisenhammer, Florian, additional, Di Pauli, Franziska, additional, Pemp, Berthold, additional, and Berger, Thomas, additional

Published
2024
Full Text
View/download PDF

7. 9. Dreiländertagung Kopfschmerz

Author

Kleinschmidt, Andreas, additional, Palla, Antonella, additional, Schankin, Christoph, additional, Bischoff, Nina, additional, Goßrau, Gudrun, additional, Kraya, Torsten, additional, Tesar, Sonja-Maria, additional, Frank, Florian, additional, and Zebenholzer, Karin, additional

Published
2024
Full Text
View/download PDF

8. Retinal layer thinning for monitoring disease-modifying treatment in relapsing multiple sclerosis—Evidence for applying a rebaselining concept.

Author

Bsteh, Gabriel, Hegen, Harald, Krajnc, Nik, Föttinger, Fabian, Altmann, Patrick, Auer, Michael, Berek, Klaus, Kornek, Barbara, Leutmezer, Fritz, Macher, Stefan, Monschein, Tobias, Ponleitner, Markus, Rommer, Paulus, Schmied, Christiane, Zebenholzer, Karin, Zulehner, Gudrun, Zrzavy, Tobias, Deisenhammer, Florian, Di Pauli, Franziska, and Pemp, Berthold

Subjects
OPTICAL coherence tomography, DISEASE duration, MULTIPLE sclerosis, DISEASE relapse, REGRESSION analysis
Abstract

Background: Employing a rebaselining concept may reduce noise in retinal layer thinning measured by optical coherence tomography (OCT). Methods: From an ongoing prospective observational study, we included patients with relapsing multiple sclerosis (RMS), who had OCT scans at disease-modifying treatment (DMT) start (baseline), 6–12 months after baseline (rebaseline), and ⩾12 months after rebaseline. Mean annualized percent loss (aL) rates (%/year) were calculated both from baseline and rebaseline for peripapillary-retinal-nerve-fiber-layer (aLpRNFLbaseline/aLpRNFLrebaseline) and macular-ganglion-cell-plus-inner-plexiform-layer (aLGCIPLbaseline/aLGCIPLrebaseline) by mixed-effects linear regression models. Results: We included 173 RMS patients (mean age 31.7 years (SD 8.8), 72.8% female, median disease duration 15 months (12-94) median baseline-to-last-follow-up-interval 37 months (18-71); 56.6% moderately effective DMT (M-DMT), 43.4% highly effective DMT (HE-DMT)). Both mean aLpRNFLbaseline and aLGCIPLbaseline significantly increased in association with relapse (0.51% and 0.26% per relapse, p < 0.001, respectively) and disability worsening (1.10% and 0.48%, p < 0.001, respectively) before baseline, but not with DMT class. Contrarily, neither aLpRNFLrebaseline nor aLGCIPLrebaseline was dependent on relapse or disability worsening before baseline, while HE-DMT significantly lowered aLpRNFLrebaseline (by 0.31%, p < 0.001) and aLGCIPLrebaseline (0.25%, p < 0.001) compared with M-DMT. Conclusions: Applying a rebaselining concept significantly improves differentiation of DMT effects on retinal layer thinning by avoiding carry-over confounding from previous disease activity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Addition of optic nerve involvement to dissemination in space criteria for multiple sclerosis – the value of optical coherence tomography (S46.009)

Author

Bsteh, Gabriel, primary, Hegen, Harald, additional, Altmann, Patrick, additional, Auer, Michael, additional, Berek, Klaus, additional, Di Pauli, Franziska, additional, Kornek, Barbara, additional, Krajnc, Nik, additional, Leutmezer, Fritz, additional, Macher, Stefan, additional, Rommer, Paulus, additional, Zebenholzer, Karin, additional, Zulehner, Gudrun, additional, Zrzavy, Tobias, additional, Deisenhammer, Florian, additional, Pemp, Berthold, additional, and Berger, Thomas, additional

Published
2023
Full Text
View/download PDF

13. Retinal layer thickness predicts disability accumulation in early relapsing multiple sclerosis

Author

Bsteh, Gabriel, primary, Hegen, Harald, additional, Altmann, Patrick, additional, Auer, Michael, additional, Berek, Klaus, additional, Di Pauli, Franziska, additional, Haider, Lukas, additional, Kornek, Barbara, additional, Krajnc, Nik, additional, Leutmezer, Fritz, additional, Macher, Stefan, additional, Rommer, Paulus, additional, Walchhofer, Lisa‐Maria, additional, Zebenholzer, Karin, additional, Zulehner, Gudrun, additional, Deisenhammer, Florian, additional, Pemp, Berthold, additional, and Berger, Thomas, additional

Published
2023
Full Text
View/download PDF

14. Erratum zu: Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe

Author

Goßrau, Gudrun, primary, Förderreuther, Stefanie, additional, Ruscheweyh, Ruth, additional, Ruschil, Victoria, additional, Sprenger, Till, additional, Lewis, David, additional, Kamm, Katharina, additional, Freilinger, Tobias, additional, Neeb, Lars, additional, Malzacher, Volker, additional, Meier, Uwe, additional, Gehring, Klaus, additional, Kraya, Torsten, additional, Dresler, Thomas, additional, Schankin, Christoph J., additional, Gantenbein, Andreas R., additional, Brössner, Gregor, additional, Zebenholzer, Karin, additional, Diener, Hans-Christoph, additional, Gaul, Charly, additional, and Jürgens, Tim P., additional

Published
2023
Full Text
View/download PDF

16. [Untitled]

Author

Goßrau, Gudrun, Förderreuther, Stefanie, Ruscheweyh, Ruth, Ruschil, Victoria, Sprenger, Till, Lewis, David, Kamm, Katharina, Freilinger, Tobias, Neeb, Lars, Malzacher, Volker, Meier, Uwe, Gehring, Klaus, Kraya, Torsten, Dresler, Thomas, Schankin, Christoph J, Gantenbein, Andreas R, Brössner, Gregor, Zebenholzer, Karin, Diener, Hans-Christoph, Gaul, Charly, and Jürgens, Tim P

Subjects
610 Medizin und Gesundheit
Published
2023
Full Text
View/download PDF

17. [Untitled]

Author

Goßrau, Gudrun, Förderreuther, Stefanie, Ruscheweyh, Ruth, Ruschil, Victoria, Sprenger, Till, Lewis, David, Kamm, Katharina, Freilinger, Tobias, Neeb, Lars, Malzacher, Volker, Meier, Uwe, Gehring, Klaus, Kraya, Torsten, Dresler, Thomas, Schankin, Christoph J, Gantenbein, Andreas R, Brössner, Gregor, Zebenholzer, Karin, Diener, Hans-Christoph, Gaul, Charly, and Jürgens, Tim P

Subjects
610 Medicine & health
Published
2023
Full Text
View/download PDF

21. Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe

Author

Goßrau, Gudrun, primary, Förderreuther, Stefanie, additional, Ruscheweyh, Ruth, additional, Ruschil, Victoria, additional, Sprenger, Till, additional, Lewis, David, additional, Kamm, Katharina, additional, Freilinger, Tobias, additional, Neeb, Lars, additional, Malzacher, Volker, additional, Meier, Uwe, additional, Gehring, Klaus, additional, Kraya, Torsten, additional, Dresler, Thomas, additional, Schankin, Christoph J., additional, Gantenbein, Andreas R., additional, Brössner, Gregor, additional, Zebenholzer, Karin, additional, Diener, Hans-Christoph, additional, Gaul, Charly, additional, and Jürgens, Tim P., additional

Published
2022
Full Text
View/download PDF

22. Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for Multiple Sclerosis.

Author

Bsteh, Gabriel, Hegen, Harald, Altmann, Patrick, Auer, Michael, Berek, Klaus, Di Pauli, Franziska, Kornek, Barbara, Krajnc, Nik, Leutmezer, Fritz, Macher, Stefan, Rommer, Paulus Stefan, Zebenholzer, Karin, Zulehner, Gudrun, Zrzavy, Tobias, Deisenhammer, Florian, Pemp, Berthold, and Berger, Thomas

Published
2023
Full Text
View/download PDF

25. Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe

Author

Goßrau, Gudrun, Förderreuther, Stefanie, Ruscheweyh, Ruth, Ruschil, Victoria, Sprenger, Till, Lewis, David, Kamm, Katharina, Freilinger, Tobias, Neeb, Lars, Malzacher, Volker, Meier, Uwe, Gehring, Klaus, Kraya, Torsten, Dresler, Thomas, Schankin, Christoph J., Gantenbein, Andreas R., Brössner, Gregor, Zebenholzer, Karin, Diener, Hans-Christoph, Gaul, Charly, Jürgens, Tim P., Goßrau, Gudrun, Förderreuther, Stefanie, Ruscheweyh, Ruth, Ruschil, Victoria, Sprenger, Till, Lewis, David, Kamm, Katharina, Freilinger, Tobias, Neeb, Lars, Malzacher, Volker, Meier, Uwe, Gehring, Klaus, Kraya, Torsten, Dresler, Thomas, Schankin, Christoph J., Gantenbein, Andreas R., Brössner, Gregor, Zebenholzer, Karin, Diener, Hans-Christoph, Gaul, Charly, and Jürgens, Tim P.

Abstract

Migräne ist die häufigste neurologische Erkrankung und kann mit einem hohen Grad der Beeinträchtigung einhergehen. Neben nichtmedikamentösen Ansätzen zur Reduktion der Migränefrequenz stehen medikamentöse Migräneprophylaxen zur Verfügung. Zur Indikation und Anwendung liegen evidenzbasierte Leitlinien der Deutschen Migräne- und Kopfschmerzgesellschaft (DMKG) und Deutschen Gesellschaft für Neurologie (DGN), Österreichischen Kopfschmerzgesellschaft (ÖKSG) sowie Schweizer Kopfwehgesellschaft (SKG) vor. Für therapierelevante Fragen wie z. B. der notwendigen und sinnvollen Dauer einer medikamentösen Migräneprophylaxe können aus bisherigen Studiendaten keine Rückschlüsse gezogen werden. Ziel dieser Übersicht ist die Formulierung von Empfehlungen zur Therapiedauer bei wirksamer medikamentöser Migräneprophylaxe, die die aktuelle Datenlage und – bei fehlenden Daten – die Expertenmeinungen berücksichtigen., Migraine is the most common neurological disorder and can be associated with a high degree of disability. In addition to non-pharmacological approaches to reduce migraine frequency, pharmacological migraine preventatives are available. Evidencebased guidelines from the German Migraine and Headache Society (DMKG), and German Society for Neurology (DGN), Austrian Headache Society (ÖKSG), and Swiss Headache Society (SKG) are available for indication and application. For therapyrelevant questions such as the duration of a pharmacological migraine prevention, no conclusions can be drawn from currently available study data. The aim of this review is to present a therapy consensus statement that integrates the current data situation and, where data are lacking, expert opinions. The resulting current recommendations on the duration of therapy for pharmacological migraine prophylaxis are shown here.

Published
2022

28. B Cell Depletion and SARS‐CoV ‐2 Vaccine Responses in Neuroimmunologic Patients

Author

Kornek, Barbara, primary, Leutmezer, Fritz, additional, Rommer, Paulus S., additional, Koblischke, Maximilian, additional, Schneider, Lisa, additional, Haslacher, Helmuth, additional, Thalhammer, Renate, additional, Zimprich, Fritz, additional, Zulehner, Gudrun, additional, Bsteh, Gabriel, additional, Dal‐Bianco, Assunta, additional, Rinner, Walter, additional, Zebenholzer, Karin, additional, Wimmer, Isabella, additional, Steinmaurer, Anja, additional, Graninger, Marianne, additional, Mayer, Margareta, additional, Roedl, Kilian, additional, Berger, Thomas, additional, Winkler, Stefan, additional, Aberle, Judith H., additional, and Tobudic, Selma, additional

Published
2022
Full Text
View/download PDF

29. Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data.

Author

Pavelic, Antun R., Wöber, Christian, Riederer, Franz, and Zebenholzer, Karin

Subjects
CALCITONIN gene-related peptide, SUMATRIPTAN, MONOCLONAL antibodies, CALCITONIN, HEALTH insurance claims, PATIENT compliance, MIGRAINE
Abstract

Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs. Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of erenumab, galcanezumab, fremanezumab, or eptinezumab in patients with migraines. Results: We identified 134 publications (89 retrospective), comprising 10 pharmaco-epidemiologic and 83 clinic-based studies, 38 case reports, and 3 other articles. None of the clinic-based studies provided follow-up data over more than one year in more than 200 patients. Findings suggest that there are reductions in health insurance claims and days with sick-leave as well as better treatment adherence with anti-CGRP-mAbs. Effectiveness, reported in 77 clinic-based studies, was comparable to randomized controlled trials. A treatment pause was associated with an increase in migraine frequency, and switching to another antibody resulted in a better response in some of the patients. Adverse events and safety issues were addressed in 86 papers, including 24 single case reports. Conclusion: Real-world data on anti-CGRP-mAbs are limited by retrospective data collection, small patient numbers, and short follow-up periods. The majority of papers seem to support good effectiveness and tolerability of anti-CGRP-mAbs in the real-world setting. There is an unmet need for large prospective real-world studies providing long-term follow-ups of patients treated with anti-CGRP-mAbs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Replication study of multiple sclerosis (MS) susceptibility alleles and correlation of DNA-variants with disease features in a cohort of Austrian MS patients

Author

Schmied, Mascha C., Zehetmayer, Sonja, Reindl, Markus, Ehling, Rainer, Bajer-Kornek, Barbara, Leutmezer, Fritz, Zebenholzer, Karin, Hotzy, Christoph, Lichtner, Peter, Meitinger, Thomas, Wichmann, H-Erich, Illig, Thomas, Gieger, Christian, Huber, Klaus, Khalil, Michael, Fuchs, Sigrid, Schmidt, Helena, Auff, Eduard, Kristoferitsch, Wolfgang, Fazekas, Franz, Berger, Thomas, Vass, Karl, and Zimprich, Alexander

Published
2012
Full Text
View/download PDF

31. Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score

Author

Bsteh, Gabriel, primary, Hegen, Harald, additional, Riedl, Katharina, additional, Altmann, Patrick, additional, Auer, Michael, additional, Berek, Klaus, additional, Di Pauli, Franziska, additional, Ehling, Rainer, additional, Kornek, Barbara, additional, Monschein, Tobias, additional, Rinner, Walter, additional, Schmied, Christiane, additional, Wurth, Sebastian, additional, Zebenholzer, Karin, additional, Zinganell, Anne, additional, Zrzavy, Tobias, additional, Zulehner, Gudrun, additional, Deisenhammer, Florian, additional, Rommer, Paulus, additional, Leutmezer, Fritz, additional, and Berger, Thomas, additional

Published
2021
Full Text
View/download PDF

32. Distinct Patterns of Humoral and Cellular Immune Responses Following SARS-CoV-2 mRNA Vaccination in Patients With Immune-Mediated Neurological Disorders on Anti-CD20 Therapy: A Prospective Cohort Study

Author

Kornek, Barbara, primary, Leutmezer, Fritz, additional, Rommer, Paulus S., additional, Koblischke, Maximilian, additional, Schneider, Lisa, additional, Haslacher, Helmuth, additional, Thalhammer, Renate, additional, Zimprich, Fritz, additional, Zulehner, Gudrun, additional, Bsteh, Gabriel, additional, Dal-Bianco, Assunta, additional, Rinner, Walter, additional, Zebenholzer, Karin, additional, Wimmer, Isabella, additional, Steinmaurer, Anja, additional, Graninger, Marianne, additional, Mayer, Margareta, additional, Roedl, Kilian, additional, Berger, Thomas, additional, Winkler, Stefan, additional, Aberle, Judith, additional, and Tobudic, Selma, additional

Published
2021
Full Text
View/download PDF

41. Benefits of inpatient multidisciplinary rehabilitation in multiple sclerosis

Author

Salhofer-Polanyi, Sabine, primary, Windt, Judith, additional, Sumper, Harald, additional, Grill, Hermine, additional, Essmeister, Maria, additional, Diermayr, Gudrun, additional, Zebenholzer, Karin, additional, Leutmezer, Fritz, additional, Zulehner, Gudrun, additional, Vass, Karl, additional, and Asenbaum-Nan, Susanne, additional

Published
2013
Full Text
View/download PDF

44. Prevalence, management and burden of episodic and chronic headaches---a crosssectional multicentre study in eight Austrian headache centres.

Author

Zebenholzer, Karin, Andree, Colette, Lechner, Anita, Broessner, Gregor, Lampl, Christian, Luthringshausen, Gernot, Wuschitz, Albert, Obmann, Sonja-Maria, Berek, Klaus, and Wöber, Christian

Subjects
HEADACHE diagnosis, HEADACHE treatment, ALGORITHMS, ANXIETY, CHRONIC diseases, MENTAL depression, HEADACHE, HOSPITAL emergency services, MEDICAL care use, MEDICAL cooperation, MEDICAL referrals, NEUROLOGISTS, GENERAL practitioners, QUESTIONNAIRES, RESEARCH, DISEASE management, COMORBIDITY, DISEASE prevalence, CROSS-sectional method, ANTIBIOTIC prophylaxis
Abstract

Background: Episodic and chronic headaches (EH, CH) are highly prevalent disorders. Severely affected patients are usually referred to headache centres. In Austria, at least one headache centre is available in seven of nine states, but detailed multicentre data are missing. Therefore we studied prevalence rates, use of medication and health care services, impact of headaches, and comorbid depression and anxiety. Methods: We included consecutive patients from eight Austrian outpatient headache centres. The patients filled-in the Eurolight questionnaire. In addition, the treating neurologist completed a questionnaire on clinical diagnoses and ever-before prophylactic medications. Results: Of 598 patients screened, 441 questionnaires were analysed (79% female, mean age 41.1 years). According to the Eurolight algorithm, 56.4% of the patients had EH, 38.3% had CH and 5.2% did not give their headache frequency. The prevalence rates of migraine, tension-type headache, and probable medication overuse headache (pMOH) were 48.5%, 6.3% and 15.9%, respectively. The concordance between clinical and Eurolight diagnoses was good for EH and moderate for CH. During the preceding month, acute medication was used by 90.9% of the patients and prophylactic medication by 34%. Ever-before use of five standard prophylactic drugs was recorded in 52.3%. The proportion of patients with current pharmacoprophylaxis did not differ in EH and CH, whereas ever-before use was more common in CH (62.5% was 45,3%, p = 0.02). Patients with CH significantly more often consulted general practitioners and emergency departments, had a lower quality of life and more often signs of depression and anxiety. Conclusion: This study provides comprehensive data from eight Austrian headache centres for the first time. We found a substantial number of patients with CH including pMOH and its association with more common utilization of health care facilities and greater burden. The low use of prophylactic medication requires further examination. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

50. Migraine and weather: A prospective diary-based analysis.

Author

Zebenholzer, Karin, Rudel, Ernest, Frantal, Sophie, Brannath, Werner, Schmidt, Karin, Wöber-Bingöl, Çiçek, and Wöber, Christian

Subjects
*MIGRAINE, *HEADACHE, *REGRESSION analysis, *PHYSIOLOGICAL effects of weather, *MULTIVARIATE analysis, *PHYSIOLOGICAL effects of temperature
Abstract

Aims: Weather is mentioned as a trigger factor by migraine patients most frequently. We examined the impact of meteorological factors and the impact of their day-to-day change on the risk of occurrence and persistence of headache and migraine and the correlation of subjective weather perception with objective weather data.Methods: We performed a prospective, diary-based cohort study in 238 patients suffering from migraine with or without aura. Patients had to live within 25 km of the Vienna meteorological station and were required to keep a diary for 90 days. We analysed 11 meteorological parameters and 17 synoptic weather situations. For evaluating the hazard of occurrence and persistence of migraine and headache, we performed a univariate and a stepwise multivariate Cox regression analysis. We calculated correlations between subjective weather perception and meteorological data.Results: In the uni- and multivariate analysis, a ridge of high pressure increased the risk of headache occurrence, lower mean daily wind speed increased the risk of migraine occurrence and a day-to-day change of daily sunshine duration increased the risk of migraine occurrence. A day-to-day change of the daily minimum temperature decreased the risk of migraine persistence. After correction for multiple testing, none of these findings remained statistically significant. Subjective weather perceptions did not correlate with the occurrence or persistence of migraine or headache. Subjective perception of cold and too-cold weather and of too-warm weather correlated with daily minimum, mean and maximum temperature.Conclusion: The influence of weather factors on migraine and headache is small and questionable. [ABSTRACT FROM PUBLISHER]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results